Graeme J. Moyle

Graeme J. Moyle

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications

Weight trajectories in virally suppressed people with HIV compared to matched people without HIV, and predictors of weight gain: a 3-year cohort study from the US TRIO Healthcare Network.

Weight trajectories in virally suppressed people with HIV compared to matched people without HIV, and predictors of weight gain: a 3-year cohort study from the US TRIO Healthcare Network.

Journal: Journal of acquired immune deficiency syndromes (1999)
Published: September 02, 2026

The effect of Biktarvy (B/F/TAF) on whole-body insulin sensitivity, lipid and endocrine profile in healthy volunteers.

The effect of Biktarvy (B/F/TAF) on whole-body insulin sensitivity, lipid and endocrine profile in healthy volunteers.

Journal: HIV medicine
Published: August 18, 2025

Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/ml and history of K103N mutation.

Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/ml and history of K103N mutation.

Journal: AIDS (London, England)
Published: July 31, 2025

Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption.

Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption.

Journal: AIDS (London, England)
Published: December 17, 2024

Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials.

Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials.

Journal: Journal of acquired immune deficiency syndromes (1999)
Published: September 04, 2024

Antiretrovirals and Weight Change: Weighing the Evidence.

Antiretrovirals and Weight Change: Weighing the Evidence.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: November 05, 2023

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.

Journal: The lancet. HIV
Published: May 09, 2023

Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.

Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.

Journal: The Journal of antimicrobial chemotherapy
Published: April 12, 2023

Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.

Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 20, 2023

Switching to High Genetic Barrier Integrase Inhibitors Reduces Drug-Drug Interactions in People Living With HIV.

Switching to High Genetic Barrier Integrase Inhibitors Reduces Drug-Drug Interactions in People Living With HIV.

Journal: Journal of acquired immune deficiency syndromes (1999)
Published: February 02, 2023

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 07, 2022

A Comparison of Self-reported Pain Measures Between Sensory Phenotypes in HIV-associated Sensory Neuropathy.

A Comparison of Self-reported Pain Measures Between Sensory Phenotypes in HIV-associated Sensory Neuropathy.

Journal: The journal of pain
Published: December 24, 2021
Showing 1-12 of 88

Last Updated: 09/26/2026